Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms

Leukemia Research
Patrick BrückOliver G Ottmann

Abstract

STI571 is active against Bcr/Abl-, c-kit- and platelet-derived growth factor receptor (PDGFR)-driven malignancies. Mild to moderate edema is common, whereas severe edema, body cavity effusions and subdural hygromas are rarely observed. These effects have been suggested to involve inhibition of PDGFR signaling, but predisposing factors are unknown. We examined SNPs in the PDGFR alpha and beta gene regions in STI571-treated patients with and without life-threatening edema or cerebral hygromas, and in healthy volunteers. By RFLP analysis of 15 SNPs, the frequencies of genotypes did not differ between the three groups. SNPs of PDGFR genes do not appear to play a role in patient's susceptibility to clinically severe edema formation during treatment with STI571.

References

Apr 21, 1999·Current Opinion in Cell Biology·M A Schwartz, V Baron
Sep 29, 1999·Proceedings of the National Academy of Sciences of the United States of America·R HeuchelP Soriano
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Nov 14, 2001·Lancet·A T van OosteromUNKNOWN European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J MauroBrian J Druker
Sep 5, 2002·Cancer·Bita EsmaeliMoshe Talpaz
Nov 20, 2002·Journal of Pediatric Hematology/oncology·Robert GoldsbyLars Wagner
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kannan RamarSyed A Mehdi
Jan 17, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Allan T van OosteromUNKNOWN European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Apr 12, 2003·Leukemia·C ShimazakiM Nakagawa
Jun 5, 2003·Seminars in Hematology·Martee L Hensley, John M Ford

❮ Previous
Next ❯

Citations

Oct 30, 2010·Clinical Lymphoma, Myeloma & Leukemia·Rishard Salie, Richard T Silver

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.